ak114
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Mar 15, 2022 (NCT05200273)
Timeline
Indications
Mechanism of action
- Interleukin-1 betaANTAGONIST
IL1B
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05947201 | Phase 2 | May 8, 2023 | Akeso Pharmaceuticals, Inc., Zhejiang University |
| NCT05200273 | Phase 1 | Mar 15, 2022 | Akeso Pharmaceuticals, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Akeso Pharmaceuticals, Inc. | For profit | 2 | 1 | 2 | 2022 |
| Zhejiang University | Academic/Hospital | 1 | 1 | 1 | 2023 |
2 organizations
Page 1 / 1